CELEX: 62016TA0403
Language: en
Date: 2017-11-20 00:00:00
Title: Case T-403/16: Judgment of the General Court of 20 November 2017 — Stada Arzneimittel v EUIPO — Urgo recherche innovation et développement (Immunostad) (EU trade mark — Invalidity proceedings — Application for the EU word mark Immunostad — Earlier national word mark ImmunoStim — Relative ground for refusal — Similarity of the trade marks — Likelihood of confusion — Article 8(1)(b) and Article 53(1)(a) of Regulation (EC) No 207/2009 (now Article 8(1)(b) and Article 60(1)(a) of Regulation (EU) 2017/1001) — Non-negligible part of the relevant public — Obligation to state reasons — Article 75 of Regulation No 207/2009 (now Article 94 of Regulation 2017/1001))

15.1.2018   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 13/14
            
         Judgment of the General Court of 20 November 2017 — Stada Arzneimittel v EUIPO — Urgo recherche innovation et développement (Immunostad)
   (Case T-403/16) (1)
   
   ((EU trade mark - Invalidity proceedings - Application for the EU word mark Immunostad - Earlier national word mark ImmunoStim - Relative ground for refusal - Similarity of the trade marks - Likelihood of confusion - Article 8(1)(b) and Article 53(1)(a) of Regulation (EC) No 207/2009 (now Article 8(1)(b) and Article 60(1)(a) of Regulation (EU) 2017/1001) - Non-negligible part of the relevant public - Obligation to state reasons - Article 75 of Regulation No 207/2009 (now Article 94 of Regulation 2017/1001)))
   (2018/C 013/23)
   Language of the case: English
   
      Parties
   
   
      Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: R. Kaase and J.-C. Plate, lawyers)
   
      Defendant: European Union Intellectual Property Office (represented by: initially, D. Botis and, subsequently, D. Walicka, acting as Agents)
   
      Other party to the proceedings before EUIPO, intervener before the General Court: Urgo recherche innovation et développement, formerly Société de développement et de recherche industrielle, then Vivatech (Chenôve, France) (represented by: A. Sion and A. Delafond-Nielsen, lawyers)
   
      Re:
   
   Action brought against the decision of the Fifth Board of Appeal of EUIPO of 19 April 2016 (Case R 863/2015-5), relating to invalidity proceedings between Vivatech and Stada Arzneimittel.
   
      Operative part of the judgment
   
   The General Court:
   
               1.
            
            
               Dismisses the action;
            
         
               2.
            
            
               Orders Stada Arzneimittel AG to pay the costs.
            
         
      (1)  OJ C 335, 12.9.2016.